tert-butyl N-[3-[4-(5-bromopyridin-2-yl)piperazin-1-yl]-3-oxopropyl]carbamate | 1302353-15-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: tert-butyl N-[3-[4-(5-bromopyridin-2-yl)piperazin-1-yl]-3-oxopropyl]carbamate
• CAS: 1302353-15-6
• 化学式: C₁₇H₂₅BrN₄O₃
• 分子量: 413.314
• InChiKey: SEUDRFXUQASGHW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  74.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  tert-butyl N-[3-[4-(5-bromopyridin-2-yl)piperazin-1-yl]-3-oxopropyl]carbamate 在 盐酸 、 三乙胺 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 生成 N-[3-[4-(5-bromopyridin-2-yl)piperazin-1-yl]-3-oxopropyl]quinoline-5-sulfonamide
  参考文献：
  名称：

  Development of a more highly selective M1 antagonist from the continued optimization of the MLPCN Probe ML012

  摘要：

  This Letter describes the continued optimization of an MLPCN probe molecule (ML012) through an iterative parallel synthesis approach. After exploring extensive modifications throughout the parent structure, we arrived at a more highly M-1-selective antagonist, compound 13I (VU0415248). Muscarinic subtype selectivity across all five human and rat receptors for 13I, along with rat selectivity for the lead compound (ML012), is presented. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.11.110
• 作为产物：
  描述：

  Boc-beta-丙氨酸 、 1-(5-溴吡啶)-2-哌嗪 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 生成 tert-butyl N-[3-[4-(5-bromopyridin-2-yl)piperazin-1-yl]-3-oxopropyl]carbamate
  参考文献：
  名称：

  Development of a more highly selective M1 antagonist from the continued optimization of the MLPCN Probe ML012

  摘要：

  This Letter describes the continued optimization of an MLPCN probe molecule (ML012) through an iterative parallel synthesis approach. After exploring extensive modifications throughout the parent structure, we arrived at a more highly M-1-selective antagonist, compound 13I (VU0415248). Muscarinic subtype selectivity across all five human and rat receptors for 13I, along with rat selectivity for the lead compound (ML012), is presented. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.11.110

文献信息

• Development of a more highly selective M1 antagonist from the continued optimization of the MLPCN Probe ML012
  作者：Bruce J. Melancon、Alexander P. Lamers、Thomas M. Bridges、Gary A. Sulikowski、Thomas J. Utley、Douglas J. Sheffler、Meredith J. Noetzel、Ryan D. Morrison、J. Scott Daniels、Colleen M. Niswender、Carrie K. Jones、P. Jeffrey Conn、Craig W. Lindsley、Michael R. Wood

  DOI：10.1016/j.bmcl.2011.11.110

  日期：2012.1

  This Letter describes the continued optimization of an MLPCN probe molecule (ML012) through an iterative parallel synthesis approach. After exploring extensive modifications throughout the parent structure, we arrived at a more highly M-1-selective antagonist, compound 13I (VU0415248). Muscarinic subtype selectivity across all five human and rat receptors for 13I, along with rat selectivity for the lead compound (ML012), is presented. (C) 2011 Elsevier Ltd. All rights reserved.